2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Thrombin
  5. Thrombin Inhibitor

Thrombin Inhibitor

Thrombin Inhibitors (63):

Cat. No. Product Name Effect Purity
  • HY-17567A
    Heparin sodium salt
    		Inhibitor ≥98.0%
    Heparin sodium salt (Sodium heparin) is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa. Heparin sodium salt significantly inhibits exosome-cell interactions.
  • HY-12821
    AEBSF hydrochloride
    		Inhibitor 99.90%
    AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin.
  • HY-17567C
    Heparin sodium salt (MW 15kDa)
    		Inhibitor
    Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
  • HY-N8278
    Dermatan sulphate sodium
    		Inhibitor
    Dermatan sulphate sodium is a glycosaminoglycan and thrombin inactivator with antithrombotic activity. Dermatan sulphate sodium selectively catalyzes the inactivation of thrombin by heparin cofactor II and does not interact with antithrombin III. Dermatan sulphate sodium is highly bioavailable and also reduces Bleomycin (HY-108345)-induced pulmonary fibrosis damage.
  • HY-10163
    Dabigatran
    		Inhibitor 98.05%
    Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
  • HY-10264
    Edoxaban
    		Inhibitor 99.62%
    Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research.
  • HY-10274
    Dabigatran etexilate
    		Inhibitor 99.84%
    Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
  • HY-B0375A
    Argatroban monohydrate
    		Inhibitor 99.98%
    Argatroban (monohydrate) (MD-805 (monohydrate)) is a direct, selective thrombin inhibitor.
  • HY-15664
    Bivalirudin TFA
    		Inhibitor 99.89%
    Bivalirudin TFA is a synthetic 20 residue peptide which reversibly inhibits thrombin.
  • HY-B0209
    Metolazone
    		Inhibitor 99.70%
    Metolazone (SR-720-22) is primarily used to treat congestive heart failure and high blood pressure.
  • HY-P1929
    Bivalirudin
    		Inhibitor 99.65%
    Bivalirudin, a peptide anticoagulant, is a direct thrombin inhibitor for anticoagulation in the setting of invasive cardiology, particularly percutaneous coronary intervention.
  • HY-109509
    Enoxaparin
    		Inhibitor
    Enoxaparin (PK 10169), a low-molecular-weight heparin (LMWH) derivative. Enoxaparin exerts anticoagulant activity through antithrombin III, an endogenous inhibitor of factor Xa and thrombin IIa. Enoxaparin protect the rat hippocampus against TBI (traumatic brain injury) via antioxidant and anti-inflammatory properties. Enoxaparin can be used for the research of deep vein thrombosis (DVT), pulmonary embolism, TBI and COVID-19.
  • HY-10264B
    Edoxaban tosylate monohydrate
    		Inhibitor 99.91%
    Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research.
  • HY-P2813
    Hirudin
    		Inhibitor
    Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others.
  • HY-10274A
    Dabigatran etexilate mesylate
    		Inhibitor 99.93%
    Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
  • HY-17378
    Dabigatran (ethyl ester)
    		Inhibitor 98.09%
    Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity.
  • HY-10787
    Ximelagatran
    		Inhibitor 98.24%
    Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
  • HY-77521
    Dabigatran ethyl ester hydrochloride
    		Inhibitor
    Dabigatran ethyl ester hydrochloride is a potent inhibitor of ribosyldihydronicotinamide dehydrogenase (NQO2) with an IC50 value of 0.8 μM and a thrombin inhibitor.
  • HY-B0375
    Argatroban
    		Inhibitor 99.90%
    Argatroban (MD-805) is a direct, selective thrombin inhibitor.
  • HY-129056
    Melagatran
    		Inhibitor 98.11%
    Melagatran is a direct and orally active inhibitor of thrombin, without interacting with any other enzymes in the coagulation cascade or fibrinolytic enzymes aside from thrombin. Melagatran does not require endogenous co-factors for its antithrombin effect and may help to alleviate some of the damaging effects of endotoxemia. Melagatran has the potential to provide a rational approach in the prevention of arterial occlusion.